Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06137183 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT06137183 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 79 participants.
The verdict
NCT06137183, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.
Interventions
- DRUG Placebo
- DRUG Vixarelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2025-06-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06137183
The ClinicalTrials.gov registry entry for NCT06137183 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06137183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06137183 about?
NCT06137183 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)". The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.
What is the current status of trial NCT06137183?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2024-05-01. Estimated completion is 2025-06-16.
What interventions are being tested in trial NCT06137183?
The interventions under investigation include: Placebo (DRUG), Vixarelimab (DRUG).
Who is sponsoring clinical trial NCT06137183?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.